Moderna, an American biological company, said on May 29 that in the company ’s second-phase study on the new coronavirus messenger RNA candidate vaccine (mRNA-1273), the first batch of participants in each age group has received injections and is expected to recruit 600 healthy subjects participated in the trial. 
Previous May 18, with the United States National Allergy and Infection Moderna, a biological company cooperating with the National Institute of Disease Research (NIAID), announced that the company’s new coronavirus vaccine phase 1 experiment has been positive. Among them, among the 45 human subjects in the first phase of clinical trials, 8 subjects produced a neutralizing antibody related to preventing the virus from infecting humans. In these subjects, two weeks after receiving the second dose of vaccine, the level of neutralizing antibodies against the new coronavirus reached or exceeded the levels seen in recovered patients.
Previous May 18, with the United States National Allergy and Infection Moderna, a biological company cooperating with the National Institute of Disease Research (NIAID), announced that the company’s new coronavirus vaccine phase 1 experiment has been positive. Among them, among the 45 human subjects in the first phase of clinical trials, 8 subjects produced a neutralizing antibody related to preventing the virus from infecting humans. In these subjects, two weeks after receiving the second dose of vaccine, the level of neutralizing antibodies against the new coronavirus reached or exceeded the levels seen in recovered patients.
But then, some vaccine experts raised doubts about Moderna ’s vaccine. On the one hand, the company did not publish the test results in medical journals, but only issued press releases. The second is that for the 8 subjects who produced neutralizing antibodies, they did not disclose further key information such as their age range, nor did they disclose the results of the remaining 37 subjects.
In this regard, on May 21st, Anthony Fudge, director of the National Institute of Allergy and Infectious Diseases, said in an interview with CNN that the vaccine is still under research In the early stages, the results are inconclusive and said: “Cautiously optimistic about this.”
As of May 11, the official website of the World Health Organization has registered 110 new coronary pneumonia vaccines under development, of which 8 have entered clinical trials.
Among them, the adenoviral vector vaccine of China ’s Kangxin Bio and the mRNA vaccine of Moderna of the United States are currently the fastest vaccines in the world, both in mid-March 2020 Enter clinical phase I.